Contemporary OB/GYN®

Contemporary OB/GYN® is a peer-reviewed journal providing practical information for doctors by doctors.

[Contemporary OB/GYN® @ContempOBGYN]

In our Article of the Week, we highlight the June 19th FDA approval of a labeled strength change for levonorgestrel and ethinyl estradiol transdermal birth control patch, a strength-only update that does not alter the product's composition, manufacturing process, or BMI-based prescribing limitations.

MORE:
https://t.co/OoLfCdo8As

[Contemporary OB/GYN® @ContempOBGYN]

James A. Simon MD, Reproductive endocrinologist; Infertility specialist; The George Washington University, IntimMedicine Specialists, Washington, D.C. details what could be next as far as clinical studies go for elinzanetant to treat moderate-to-severe vasomotor symptoms.

Learn more about the product’s pooled safety data by clicking here: https://t.co/QziTvA9TZi

[Contemporary OB/GYN® @ContempOBGYN]

June 24, 2026 marked 4 years since the Dobbs decision. In the post-Roe era, what does management of cesarean scar ectopic pregnancy look like?

In the article below, Patrice Trowbridge, MD and Nicole Economou, MD, MPH, explain:
https://t.co/mp3gB6rOVn

[Contemporary OB/GYN® @ContempOBGYN]

Meg Vasey, MD candidate & Anubha Arora, MD, of New York Medical College, explain how vacuum-induced and balloon tamponade devices demonstrated comparable performance across most outcomes in the treatment of postpartum hemorrhage.

More information on where the vacuum device was favored: https://t.co/vpE9kBQ4lZ

[Contemporary OB/GYN® @ContempOBGYN]

Genevieve Neal-Perry, MD PhD, and James A. Simon MD, speak to elinzanetant’s impact since it received FDA approval in October 2025 to treat moderate-to-severe vasomotor symptoms associated with menopause. The experts highlight its effectiveness and recent pooled safety data from 4 placebo-controlled trials. #VMS #menopause

More on patient experience and clinical safety data: https://t.co/HfT7KPVy3Q

[Contemporary OB/GYN® @ContempOBGYN]

Thank you, Quynh Tran, MD, for speaking with us about educational gaps in the Midwest region regarding sexual health curriculum. In a study presented at #ACOG2026, Tran and colleagues found that "while schools did include foundational topics like anatomy, embryology, STIs, and birth control, there were significant gaps in other, more clinically nuanced and patient board scenarios."

Watch the full interview here: https://t.co/6m8aoVmZzT

[Contemporary OB/GYN® @ContempOBGYN]

In another edition of our recent conversation from the Sleep Research Society annual meeting, Stephanie Faubion, MD, MBA, FACP, MSCP, IF, director of the Mayo Clinic Center for Women's Health, explained that shared decision-making around non-hormonal #VMS and sleep management requires moving through contraindications, patient preferences, and monitoring burdens together.

WATCH: https://t.co/ZS80J07ssg

[Contemporary OB/GYN® @ContempOBGYN]

A 2-MDM panel detected endometrial #cancer in self-collected vaginal fluid with 96% sensitivity and 82% specificity, according to a marker reduction study published in Gynecologic Oncology.

Watch our full interview with study author Elle Kielar Grevstad, PhD, who explains the reasoning behind a new approach to EC detection in addition to what research is next.

WATCH: https://t.co/wDSNdaz56A

[Contemporary OB/GYN® @ContempOBGYN]

"Hormones, it's just one piece of the puzzle," says Jessica (Schiffman) Gaulton MD, MPH, CEO and founder of FamilyWell Health. Insomnia, depression, anxiety, and brain fog are the most common symptoms women report during perimenopause and menopause — yet most providers receive no formal training to recognize or treat them. 

In our Article of the week, Gaulton highlights knowledge gaps and details the announcement of FamilyWell Health newly-launched Menopause Hub.

MORE: https://t.co/trwIPWtgzz

[Contemporary OB/GYN® @ContempOBGYN]

Sleep disturbance and VMS are among the most prevalent and disruptive symptoms of the #menopause transition and are known to affect quality of life.

According to recent data presented at #SLEEP2026, sleep disturbance was independently associated with lower HRQoL relating to role-physical, role-emotional, and energy/fatigue, with no change in these associations over time.

Learn more: https://t.co/WN6Ub2QdjK

[Contemporary OB/GYN® @ContempOBGYN]

New #contraception news from the FDA:

Today, the federal agency approved an updated labeled strength for levonorgestrel and ethinyl estradiol (TWIRLA; EXELTIS USA) based on residual drug results from Study ATI-CL28, with the new strength expected on the market in September or October of 2026.

LEARN MORE: https://t.co/LHuVOCRtlp

[Contemporary OB/GYN® @ContempOBGYN]

Thank you, Fiona Baker, PhD, for speaking with us from the Sleep Research Society Annual meeting and explaining links between vasomotor symptoms and sleep disturbances while highlighting data from the NIRVANA trial of #elinzanetant use in postmenopausal women. #SLEEP2026

Click here to watch our full discussion and to learn more about how elinzanetant reduced wakefulness after #sleep onset in #postmenopausal women: https://t.co/niycIclkBy

[Contemporary OB/GYN® @ContempOBGYN]

New treatment approved by the #FDA:

Today, the federal agency approved tebipenem pivoxil as first oral carbapenem antibiotic for complicated urinary tract infections, including pyelonephritis, based on the phase 3 PIVOT-PO trial.

Full approval details here: https://t.co/DYmyAczZAp

[Contemporary OB/GYN® @ContempOBGYN]

Learn key insights on screening & diagnosing postpartum depression (PPD) in the on-demand sponsored series Expert Insights on PPD. Hear experts discuss PPD collaborative care & listen to a mock patient-physician discussion. Watch now: https://t.co/J3I5x1Gxhr #PPD #OBGYN

[Contemporary OB/GYN® @ContempOBGYN]

Thank you, Stephanie Faubion, MD, MBA, FACP, MSCP, IF, for discussing both #elinzanetant and #fezolinetant for VMS management and lack of sleep. As Faubion explains, these treatments could serve as first-line options rather than SSRIs or gabapentin. #SLEEP2026

Watch our full discussion stemming from Sleep Research Society (https://t.co/FQ2pNwhyhk) 2026 meeting: https://t.co/DjO7mPflxT

[Contemporary OB/GYN® @ContempOBGYN]

When “free” isn’t free: the coverage gaps undermining breast cancer screening:

Read more from Barbara Levy, MD, FACOG, FACS:
https://t.co/rgD8t0qLSW

[Contemporary OB/GYN® @ContempOBGYN]

Video: Mark Simon, MD, MMM (@mnsmd) highlights the role of the OB hospitalist as a collaborative partner who can initiate rapid treatment for hypertensive crises in the hospital setting.

Watch the interview here: https://t.co/hXQobz63lO

[Contemporary OB/GYN® @ContempOBGYN]

Melissa Loseke, DO, Medical Director, Joi+Blokes, Omaha, Nebraska, explains the importance of labs when using testosterone replacement therapy (TRT) in women.

“I definitely think that labs are key,” Loseke added. “It is, number one, just making sure that you're following biomarkers as well as symptom improvement with the [patients], and making sure that the education is there so that you feel comfortable in your prescribing and understanding all the different options from a testosterone perspective.”

Watch the full discussion here: https://t.co/Ji46IvfUPS

[Contemporary OB/GYN® @ContempOBGYN]

Jennifer Hoskovec, MS, CGC, who serves as BillionToOne’s VP of Medical Affairs, explains part of the validation process for the recently announced Unity Confirm non-invasive test for high-risk pregnancy screenings.

Learn more about the test here, from our full interview with Hoskovec and BillionToOne Chief Medical Officer, Haywood Brown, MD: https://t.co/1bbVhzjquA

[Contemporary OB/GYN® @ContempOBGYN]

Genevieve Neal-Perry, MD, PhD, Robert A. Ross Distinguished Professor and chair of the Department of Obstetrics and Gynecology at the University of North Carolina School of Medicine, Chapel Hill, explains the mechanism of action for both elinzanetant and fezolinetant for vasomotor symptoms.

Watch the full interview here, which includes a breakdown of fezolinetant data: https://t.co/NfQ6CrDWdI